Colmenares-Mejía, Claudia C.Quintero-Lesmes, Doris C.Bautista-Niño, Paula K.Guio Mahecha, ElizabethBeltrán Avendaño, MónicaDíaz Martínez, Luis AlfonsoOrtiz Serrano, RicardoPáez Leal, María CarolinaMonterrosa-Castro, ÁlvaroMesa Restrepo, Clara MariaMonsalve, GermánSanín-Blair, EnriqueSaldarriaga, WilmarLuna, María LucreciaCasas, Juan P.Serrano Díaz, Norma2025-08-222025-08-2220200916 - 9636https://hdl.handle.net/11227/20084Pentraxin-3 has been reported as a promising biomarker of pre-eclampsia and its severity; however, available studies have small sample sizes, and analyses are not always adjusted for confounders. The aim of this study is to establish the strength of the association between maternal Pentraxin-3 level and pre-eclampsia or HELLP syndrome. It was a case-control study. Women with pre-eclampsia or HELLP syndrome were defined as cases, and women with healthy pregnancies at term (>37 weeks) were classified as controls. Plasma concentrations of Pentraxin-3 were determined at the time of delivery by quantitative enzyme immunoassay. Associations between Pentraxin-3 and pre-eclampsia and HELLP syndrome were assessed by multinomial logistic regression. Subsidiary analysis for the time of disease onset was also carried out. Odds ratios and 95% confidence intervals are reported. A total of 1024 pregnant women were included (461 controls, 368 preeclampsia, 195 HELLP). A positive log-linear relationship was found between the top pentraxin-3 quintile and HELLP syndrome. After adjustment for confounders (maternal age, ethnicity, socioeconomic position, date and place of recruitment, family history of pre-eclampsia, smoking, body mass index at beginning of pregnancy, gestational age and multiple pregnancy), the strength of the association was higher for HELLP syndrome [OR 1.13 (95% CI 1.08; 1.18)] than for preeclampsia [OR 1.03 (95% CI 1.03; 1.10)]. No difference according to time of onset or pentraxin-3 level was found. In summary, pentraxin-3 level was associated with pre-eclampsia, but it was more strongly associated with HELLP syndrome. Longitudinal studies with a lower probability of residual confounding are necessary to improve our knowledge about the role of pentraxin-3 in pre-eclampsia.application/pdfenghttps://creativecommons.org/licenses/by-nc/4.0/Artículo de revistaAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)http://purl.org/coar/access_right/c_abf21348 - 4214info:eu-repo/semantics/openAccess3. Ciencias Médicas y de la SaludPregnancy complicationsEclampsiaChildbirth - ComplicationsHypertensionPregnancyODS 3: Salud y bienestar. Garantizar una vida sana y promover el bienestar de todos a todas las edades